Nimotuzumab Combined With Chemoradiotherapy for Unresectable Locally Advanced Squamous Cell Lung Cancer

Model scores of the 29,894 trials active now.

Model score 16% for any early termination, 11% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2020-10-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: cancersquamouscell lungchemotherapyto determine
  Phrases that lowered it: efficacy andthe efficacylesionsother clinicalevaluation
• Sponsor's past termination rate: 1.3% (lowers risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 106 (lowers risk) · Sponsor's track record
• Disease area, cancer: Yes (raises risk) · Disease area
• Design: parallel (raises risk) · Design
• Drug's FAERS reports marked serious: 96.3% (raises risk) · Drug's FDA history
• Maximum age: 75 (lowers risk) · Who can join
• Drug's FAERS reports with a death: 23.2% (raises risk) · Drug's FDA history
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Primary purpose: treatment (raises risk) · Design
• Responsible party: principal investigator (lowers risk) · Design
• Sponsor's past trials: 79 (lowers risk) · Sponsor's track record
• Number of arms: 2 (raises risk) · Design
• Blinding: none (raises risk) · Design
• Has a data monitoring committee: No (lowers risk) · Design
• Collaborators: 0 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• A Study of Chemoradiation Associated with Nimotuzumab As the Treatment of Locally Advanced Esophageal Cancer NCT01249352 · started 2009 · scored riskier than 46% of active trials completed
• Nimotuzumab in Combination With Chemoradiation for Esophageal Cancer NCT00950417 · started 2009 · scored riskier than 36% of active trials completed
• A Study of Nimotuzumab in Combination With External Radiotherapy in Non-Small Cell Lung Cancer NCT00369447 · started 2009 · scored riskier than 99% of active trials terminated
• Nimotuzumab in Combination With Radiotherapy for Esophageal Cancer NCT02591784 · started 2008 · scored riskier than 33% of active trials completed
• Nimotuzumab in Combined With Chemotherapy for Treatment of IVB Stage,Rrecurrent or Persistent Cervical Carcinoma NCT06781073 · started 2017 · scored riskier than 70% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.